Strategic Partnerships Dignify's lead assets DTI-117 and DTI-301 are transitioning through clinical development, and recent conference presentations help validate their path to market. With NIH-supported research and active participation at investor events, the company is well-positioned for co-development, licensing, or CRO partnerships to advance trials. As a lean organization, they could accelerate timelines by engaging experienced development and regulatory partners.

Funding and Validation NIH funding and recognition as Praxis SCI Accelerate establish credibility and de-risk collaboration discussions for potential licensees or fee-for-service partners. Given modest current revenue and limited funding, a milestone-based deal with a pharma partner or a CRO could provide runway for late-stage development and commercialization.

Market Need There is a sizable unmet need for restoring continence in patients with spinal cord injury, spina bifida, and other neurological conditions, presenting a compelling value proposition for payers and health systems. Opportunities exist to approach hospitals, neurology and urology clinics, rehab centers, and patient advocacy groups to discuss adoption, reimbursement pathways, and real-world outcomes.

Leadership Credibility Leadership changes, including new board members and a Duke-based principal investigator, bolster clinical and academic credibility for large collaborations. This leadership profile can help open doors with major pharma, academic medical centers, and contract research organizations for co-development, data-sharing, and sponsored trials.

Market Presence Digital and event-based visibility signals a growing partner-ready pipeline. Use BIO conferences and investor events to generate introductions to potential licensees, CROs, and distributors, and align messaging around patient quality-of-life outcomes to drive rapid engagement.